Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.68 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412034 | 0.97 | MAOB (0.73) | MRGPRX4MAOBNR4A2SMPD1PTPN1 | |
| SCHEMBL976424 | 0.97 | MAOB (0.73) | MRGPRX4MAOBNR4A2SMPD1PTPN1 | |
| SCHEMBL1122722 | 0.93 | MAOB (0.68) | MRGPRX4MAOBNR4A2SMPD1PTPN1 | |
| SCHEMBL10411878 | 0.93 | MRGPRX4 (0.77) | MRGPRX4MAOBNR4A2SMPD1CYSLTR1 | |
| SCHEMBL1122731 | 0.90 | SMN1; SMN2 (0.64) | MRGPRX4MAOBNR4A2SMPD1PTPN1 | |
| SCHEMBL1171850 | 0.89 | MRGPRX4 (0.65) | MRGPRX4MAOBNR4A2SMPD1PTPN1 | |
| SCHEMBL2654709 | 0.89 | MRGPRX4 (0.71) | MRGPRX4MAOBNR4A2SMPD1CYSLTR1 | |
| SCHEMBL2652322 | 0.88 | MRGPRX4 (0.67) | MRGPRX4MAOBNR4A2SMPD1CYSLTR1 | |
| SCHEMBL8231874 | 0.87 | MAOB (0.75) | MRGPRX4MAOBNR4A2CYSLTR1NR1H4 | |
| SCHEMBL7719391 | 0.87 | MRGPRX4 (0.70) | MRGPRX4MAOBNR4A2SMPD1CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| CN-1835914-A | New benzamides as PPAR[upsilon] modulators | S A L V A T LAB SA (ES) | 2006-09-20 | — | — | CN | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1644321-A2 | NEW BENZAMIDES AS PPATY MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004110983-A2 | NEW BENZAMIDES AS PPARϒ MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | MRGPRX4 1739/4885MAOB 1188/4885NR4A2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.